186 related articles for article (PubMed ID: 12137306)
41. Hormone replacement therapy in Germany: determinants and possible health-related outcomes. Results of National Health Surveys from 1984 to 1999.
Du Y; Melchert HU; Schäfer-Korting M
Maturitas; 2005; 52(3-4):223-34. PubMed ID: 16040212
[TBL] [Abstract][Full Text] [Related]
42. The effect of hormone therapy on the health-related quality of life in elderly women.
Eviö S; Pekkarinen T; Sintonen H; Tiitinen A; Välimäki MJ
Maturitas; 2007 Feb; 56(2):122-8. PubMed ID: 17158003
[TBL] [Abstract][Full Text] [Related]
43. Hormone therapy for the management of the menopause in Ecuador: perception, use and knowledge among middle-aged women.
Leon-Leon P; Chedraui P; Hidalgo L; Ortiz F; Castelo-Branco C
Gynecol Endocrinol; 2008 Oct; 24(10):580-5. PubMed ID: 19012102
[TBL] [Abstract][Full Text] [Related]
44. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.
Almeida S; Fiegenbaum M; de Andrade FM; Osório-Wender MC; Hutz MH
Maturitas; 2006 May; 54(2):119-26. PubMed ID: 16242874
[TBL] [Abstract][Full Text] [Related]
45. Hormones down under: hormone therapy use after the Women's Health Initiative.
Travers C; O'Neill SM; Khoo SK; King R
Aust N Z J Obstet Gynaecol; 2006 Aug; 46(4):330-5. PubMed ID: 16866795
[TBL] [Abstract][Full Text] [Related]
46. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy.
Hoffmeister M; Raum E; Krtschil A; Chang-Claude J; Brenner H
Clin Pharmacol Ther; 2009 Oct; 86(4):416-24. PubMed ID: 19606090
[TBL] [Abstract][Full Text] [Related]
47. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
[TBL] [Abstract][Full Text] [Related]
48. Menopause characteristics of women with physical disabilities from poliomyelitis.
Kalpakjian CZ; Quint EH; Tate DG; Roller S; Toussaint LL
Maturitas; 2007 Feb; 56(2):161-72. PubMed ID: 16930875
[TBL] [Abstract][Full Text] [Related]
49. Personal use of hormone therapy by postmenopausal women doctors and male doctors' wives in Italy after the publication of WHI trial.
Biglia N; Ujcic E; Kubatzki F; Sgandurra P; Robba C; Ponzone R; Sismondi P
Maturitas; 2006 May; 54(2):181-92. PubMed ID: 16330170
[TBL] [Abstract][Full Text] [Related]
50. The declining impact of race and insurance status on hormone replacement therapy.
Stafford RS; Saglam D; Causino N; Blumenthal D
Menopause; 1998; 5(3):140-4. PubMed ID: 9774758
[TBL] [Abstract][Full Text] [Related]
51. [Psychological aspects of decision-making by women about using hormone replacement therapy].
Olejek A
Wiad Lek; 2000; 53(1-2):92-7. PubMed ID: 10806928
[TBL] [Abstract][Full Text] [Related]
52. Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers.
Derby CA; Hume AL; McPhillips JB; Barbour MM; Carleton RA
Am J Obstet Gynecol; 1995 Aug; 173(2):544-50. PubMed ID: 7645633
[TBL] [Abstract][Full Text] [Related]
53. [Decrease of labor absenteeism associated with hormone replacement therapy in postmenopausal women].
Blümel JE; Sáez L; Roncagliolo ME; Tacla X; Brandt A
Rev Med Chil; 1995 Aug; 123(8):948-53. PubMed ID: 8657962
[TBL] [Abstract][Full Text] [Related]
54. Lower urinary tract infections and the effects of hormone therapy in postmenopausal women in the Zagreb region.
Hunjak B; Findri-Gustek S; Kolarić B; Fistonić I; Lukić-Grli A; Vojnović G
Coll Antropol; 2012 Sep; 36(3):841-6. PubMed ID: 23213942
[TBL] [Abstract][Full Text] [Related]
55. [Hormone replacement therapy among Norwegian women. Self-reported use and sales of estrogen preparations].
Søgaard AJ; Fønnebø V; Magnus JH; Tollan A
Tidsskr Nor Laegeforen; 1998 Feb; 118(4):590-5. PubMed ID: 9520588
[TBL] [Abstract][Full Text] [Related]
56. Specific and total carotenoid intakes among oral contraceptive and estrogen hormone users in the United States.
Nebeling LC; Forman MR; Graubard BI; Snyder RA
J Am Coll Nutr; 1996 Dec; 15(6):608-13. PubMed ID: 8951739
[TBL] [Abstract][Full Text] [Related]
57. Who are the Zimbabwean loop users? The social and demographic characteristics of Zimbabwean IUCD users.
Woelk G
Cent Afr J Med; 1995 Apr; 41(4):113-8. PubMed ID: 7788681
[TBL] [Abstract][Full Text] [Related]
58. Concomitant medication use in postmenopausal women using estrogen therapy.
Small R; Friedman GD; Ettinger B
Menopause; 2001; 8(2):120-6. PubMed ID: 11256872
[TBL] [Abstract][Full Text] [Related]
59. [Little health benefit gained with hormone replacement therapy in postmenopausal women in the Netherlands].
van Maanen H
Ned Tijdschr Geneeskd; 2001 Jul; 145(29):1429. PubMed ID: 11494698
[No Abstract] [Full Text] [Related]
60. Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use.
Costas L; Sequera VG; Quesada P; Altzibar JM; Lope V; Pérez-Gómez B; Benavente Y; Martín V; Casabonne D; Robles C; Llorca J; Moreno-Iribas C; Fernandez-Tardón G; Moreno V; Caballero-Granado FJ; Salas D; Jiménez-Moleón JJ; Marcos-Gragera R; Chirlaque MD; Amiano P; Molina AJ; Castaño-Vinyals G; Aragonés N; Kogevinas M; Pollán M; de Sanjosé S
Menopause; 2015 Oct; 22(10):1138-46. PubMed ID: 26125537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
